InsidersTradesSigma
Follow the Passage BIO, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Passage BIO, Inc. has recorded 38 public disclosures. Market capitalisation: €15.5m. The latest transaction was reported on 12 January 2026 (Levée d'options). Among the most active insiders: ORBIMED ADVISORS LLC. The full history is free.
38
Insider Decl.
n/a
Thresholds
€3m
13 ops.
Buy Volume
€498,455
11 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 January 2026
Declarations38 total
5,000 sharesCommon StockSEC:0001987062-26-000001:0
10,000 sharesCommon StockSEC:0001949693-26-000001:0
325 shares@ US$6.95580.4% of flowCommon stock, $0.0001 par value per share (Common Stock)SEC:0000902664-25-004079:0
Canonical exit: 10 Dec 2025 (T+90)
13,123 shares@ US$5.436114.1% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-003152:0
Canonical exit: 20 Oct 2025 (T+90)
231,600 shares@ US$0.352.0% of flowCommon StockSEC:0000947871-25-000629:0
78,049 shares@ US$0.340.4% of flowCommon StockSEC:0000947871-25-000423:0
10,326 shares@ US$0.380.1% of flowCommon StockSEC:0000947871-25-000415:0
8,000 sharesCommon StockSEC:0001415889-25-003728:0
126,209 shares@ US$0.661.5% of flowCommon StockSEC:0000947871-25-000034:0
19,481 shares@ US$0.770.3% of flowCommon StockSEC:0000947871-25-000021:0
373,645 shares@ US$0.645162.3% of flowCommon stock, $0.0001 par value per shareSEC:0000902664-24-007075:0
Canonical exit: 27 Mar 2025 (T+90)
230,321 shares@ US$0.602.5% of flowCommon StockSEC:0000947871-24-001037:0
54,181 shares@ US$0.840.8% of flowCommon StockSEC:0000947871-24-000998:0
76,200 shares@ US$0.791.1% of flowCommon StockSEC:0000947871-24-000995:0
259,998 shares@ US$0.564137.7% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-24-006799:0
Canonical exit: 23 Feb 2025 (T+90)
39,300 shares@ US$0.710.5% of flowCommon StockSEC:0000947871-24-000769:0
63,100 shares@ US$0.740.8% of flowCommon StockSEC:0000947871-24-000763:0
5,000 sharesCommon StockSEC:0001415889-24-003637:0
4,000 sharesCommon StockSEC:0001415889-24-003640:0
50,000 sharesCommon StockSEC:0001209191-24-000365:0
30,000 sharesCommon StockSEC:0001209191-24-000367:0
50,000 sharesCommon StockSEC:0001209191-24-000369:0
31,250 shares0Common StockSEC:0001209191-23-043998:0
617,382 shares@ US$0.849.0% of flowCommon StockSEC:0000947871-23-000712:0
Canonical exit: 25 Sept 2023 (T+90)
12,500 shares0Common StockSEC:0001209191-23-038345:0
25 of 38 declarations
关于 Passage BIO, Inc.
Passage Bio, Inc. (NASDAQ: PASG) 是一家总部位于宾夕法尼亚州费城的美国临床阶段基因药物公司。该公司成立于 2017 年 7 月，专注于开发针对神经退行性疾病潜在生物学的一次性、疾病修饰疗法。对于投资者而言，Passage Bio 仍然是一个高风险、处于开发阶段的生物技术公司，迄今为止没有可观的商业收入，其商业模式仍以临床执行、监管里程碑和外部融资为中心。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf)) 该公司的起源与其与宾夕法尼亚大学基因治疗项目的研究和合作框架密切相关，该框架帮助建立了 Passage Bio 的科学基础和早期管线。这项合作最初围绕罕见的单基因中枢神经系统疾病建立，后来支持了该公司更广泛地进军神经退行性疾病领域。这种历史联系仍然很重要，因为它支撑了 Passage Bio 获得科学知识和基因治疗专业知识的途径。([nasdaq.com](https://www.nasdaq.com/press-release/passage-bio-announces-expansion-of-gene-therapy-collaboration-with-university-of)) Passage Bio 的主要临床资产是 PBFT02，这是一种正在开发用于额颞叶痴呆（包括与颗粒蛋白前体缺乏相关的 FTD）的候选药物。该公司将该机制描述为提高颗粒蛋白前体水平以恢复溶酶体功能并可能减缓疾病进展。从战略上讲，这使得 Passage Bio 处于中枢神经系统生物技术市场中一个高度专业化的细分市场，在该市场中，科学差异化至关重要，但临床和监管风险也很大。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf)) 从竞争角度来看，Passage Bio 尚未达到商业化阶段，在规模、销售基础设施或多元化产品收入方面不具备竞争力。相反，其价值主张在于管线选择性、平台可信度以及将少量基因靶向项目推进到后期开发阶段的潜力。美国证券交易委员会的文件显示，该公司持续亏损，累计赤字巨大，并持续依赖股权融资、合作和许可协议来资助运营。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf)) 最近的发展值得关注。该公司报告了 upliFT-D 试验的最新中期数据，并表示正在进行战略审查；它还披露已聘请 Wedbush PacGrow 作为该过程的财务顾问。Passage Bio 在 2025 年和 2026 年继续在投资者会议上发表演讲，反映了在处理临床、监管和公司优先事项的同时持续参与资本市场。对于关注内幕交易活动的美国投资者而言，这家纳斯达克上市公司仍然是一个投机性生物技术故事，其中执行、融资灵活性和 PBFT02 的读数是关键驱动因素。([nasdaq.com](https://www.nasdaq.com/press-release/passage-bio-reports-updated-interim-data-uplift-d-trial-and-provides-regulatory-and))
